Carisma Therapeutics Statistics Share Statistics Carisma Therapeutics has 41.79M
shares outstanding. The number of shares has increased by 0.5%
in one year.
Shares Outstanding 41.79M Shares Change (YoY) 0.5% Shares Change (QoQ) 0% Owned by Institutions (%) 11.51% Shares Floating 21.12M Failed to Deliver (FTD) Shares 3 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 694.37K, so 1.66% of the outstanding
shares have been sold short.
Short Interest 694.37K Short % of Shares Out 1.66% Short % of Float 1.89% Short Ratio (days to cover) 1.04
Valuation Ratios The PE ratio is -0.29 and the forward
PE ratio is -0.68.
Carisma Therapeutics's PEG ratio is
0.01.
PE Ratio -0.29 Forward PE -0.68 PS Ratio 0.88 Forward PS 0.3 PB Ratio -0.62 P/FCF Ratio -0.29 PEG Ratio 0.01
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Carisma Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 1.48,
with a Debt / Equity ratio of -0.09.
Current Ratio 1.48 Quick Ratio 1.48 Debt / Equity -0.09 Debt / EBITDA -0.04 Debt / FCF -0.04 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $426.78K Profits Per Employee $-1.31M Employee Count 46 Asset Turnover 0.64 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -50.5% in the
last 52 weeks. The beta is 2.79, so Carisma Therapeutics's
price volatility has been higher than the market average.
Beta 2.79 52-Week Price Change -50.5% 50-Day Moving Average 0.25 200-Day Moving Average 0.57 Relative Strength Index (RSI) 56.84 Average Volume (20 Days) 13,643,998
Income Statement In the last 12 months, Carisma Therapeutics had revenue of 19.63M
and earned -60.48M
in profits. Earnings per share was -1.46.
Revenue 19.63M Gross Profit 16.28M Operating Income -62.18M Net Income -60.48M EBITDA -58.83M EBIT -60.48M Earnings Per Share (EPS) -1.46
Full Income Statement Balance Sheet The company has 17.91M in cash and 2.48M in
debt, giving a net cash position of 15.43M.
Cash & Cash Equivalents 17.91M Total Debt 2.48M Net Cash 15.43M Retained Earnings -305.58M Total Assets 15.95M Working Capital 3.51M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -59.92M
and capital expenditures -123K, giving a free cash flow of -60.04M.
Operating Cash Flow -59.92M Capital Expenditures -123K Free Cash Flow -60.04M FCF Per Share -1.45
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -316.72% and -308.05%.
Gross Margin 100% Operating Margin -316.72% Pretax Margin -308.05% Profit Margin -308.05% EBITDA Margin -290.97% EBIT Margin -316.72% FCF Margin -305.83%
Dividends & Yields CARM does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for CARM is $1,
which is 100% higher than the current price. The consensus rating is "Hold".
Price Target $1 Price Target Difference 100% Analyst Consensus Hold Analyst Count 6
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Mar 8, 2023. It was a
backward
split with a ratio of 1:20.
Last Split Date Mar 8, 2023 Split Type backward Split Ratio 1:20
Scores Altman Z-Score -35.04 Piotroski F-Score 2
